| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | Applied Biological Laboratories Inc. | 760 Parkside Ave Rm 317 | Brooklyn | NY | 11226-1784 | KINGS | USA | R43IP001129 | Novel Anti-Viral Formulation to Prevent Rhinovirus and Influenza | 03 | 1 | CDC | 1/19/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | Applied Biological Laboratories Inc. | 760 Parkside Ave Rm 317 | Brooklyn | NY | 11226-1784 | KINGS | USA | R43IP001129 | Novel Anti-Viral Formulation to Prevent Rhinovirus and Influenza | 01 | 1 | CDC | 11/19/2019 | $0 |
| | 2020 | 2019 | Applied Biological Laboratories Inc. | 760 Parkside Ave Rm 317 | Brooklyn | NY | 11226-1784 | KINGS | USA | R43IP001129 | Novel Anti-Viral Formulation to Prevent Rhinovirus and Influenza | 02 | 1 | CDC | 11/20/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $224,399 ) |
| | 2019 | 2019 | Applied Biological Laboratories Inc. | 760 Parkside Ave Rm 317 | Brooklyn | NY | 11226-1784 | KINGS | USA | R43IP001129 | Novel Anti-Viral Formulation to Prevent Rhinovirus and Influenza | 00 | 1 | CDC | 8/7/2019 | $224,399 |
|
|
